iPLEDGE Weaknesses: Is It Time to Address the Flaws?

被引:0
|
作者
Cyrulnik, Amanda A. [1 ,2 ]
Gewirtzman, Aron J. [1 ,3 ]
Paz, Karin Blecher [1 ]
Glick, Jaimie B. [2 ]
Anam, Anika K. [2 ]
Carrasco, Daniel A. [3 ]
Shalita, Alan R. [2 ]
Cohen, Steven R. [1 ]
机构
[1] Albert Einstein Coll Med, Unified Div Dermatol, Bronx, NY 10467 USA
[2] SUNY Downstate Dept Dermatol, Brooklyn, NY USA
[3] Austin Dermatol Associates, Austin, TX USA
关键词
ELECTRONIC MEDICAL-RECORD; ISOTRETINOIN;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The observance during acne follow-ups that information stored within iPLEDGE was discordant with medical charts prompted this study. Objective: To evaluate the information acquired and stored within iPLEDGE as it compares to medical charts with a goal of assessing the efficacy of iPLEDGE as a database. Methods: This is a multicenter retrospective chart review analyzing congruence and discrepancies between medical chart documentation and iPLEDGE data for all patients who received at least a single dose of isotretinoin from the primary investigators between January 2006 and November 2010. Results: A total of 357 charts were analyzed. Overall congruence between medical chart documentation and iPLEDGE data was observed in only 73.1 % of cases. The discrepancy (N=96) was due to a missed dose (prescription recorded in chart but not in iPLEDGE) in 81.4% of cases, or an addition (medication dispensed per iPLEDGE without corresponding chart documentation) in the remainder of cases. Of note, several charts had multiple discrepancies (N=249 total discrepancies). Limitations: Retrospective chart review study. Conclusion: Given the large percentage of discordant data, our findings question the efficacy of the iPLEDGE system, which is designed to monitor every dispensed isotretinoin dose.
引用
收藏
页码:97 / 102
页数:6
相关论文
共 50 条